COMP <GO>
COGT vs PTCT // DIVIDEND YIELD & FCF PAYOUT SAFETY
Cogent Biosciences Inc. (NASDAQ) VS. PTC Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: COGT 3
— PTCT 8
■ METRIC PARITY
LAST: $29.73 (-4.16%) • MKT CAP: $5.38B
dividend-safety
0.00%
LAST: $60.88 (+1.52%) • MKT CAP: $5.01B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COGT VS. PTCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COGT | PTCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 85.00% | -120.00 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 6.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.80% | 13.05% | -17.85 | PTCT | /fcf-yield <GO> |
| Operating Margin | -21.50% | 50.10% | -71.60 | PTCT | /operating-margins <GO> |
| Net Profit Margin | -21.20% | 39.50% | -60.70 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 114.50% | -92.50 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.84 | 1.73 | +9.11 | COGT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.2 | 43.2 | +4.00 | COGT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.15 | -0.10 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 6.6x | +15.40 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $5.01B | $372.6M | COGT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COGT REV | PTCT REV | COGT GROSS % | PTCT GROSS % | COGT FCF | PTCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $933.4M | $1.73B | — | — | -$266.0M | $702.3M |
| FY 2024 | $772.6M | $806.8M | — | — | -$208.4M | -$114.2M |
| FY 2023 | $582.8M | $937.8M | — | — | -$153.6M | -$200.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COGT // BETA 1.05
PTCT // BETA 1.15